Phase Holographic (PHI) Q1 24/25 earnings summary

Executive summary

• Net sales for Q1 2024/25 were 1,338 KSEK, down from 2,726 KSEK year-over-year, due to strategic investments in onboarding new sales partners and market channels, expected to drive growth later in 2024.

• Expanded collaborations with leading research institutions, notably University College London, and entered new markets in Spain, Portugal, and the Nordics through new distribution agreements.

• Secured approval for dual listing on the US OTCQB market to enhance liquidity and support growth in regenerative medicine.

• Board changes included the retirement of Leland Foster and the appointment of John Moore, an experienced life sciences executive.

Financial highlights

• Net sales: 1,338 KSEK (down from 2,726 KSEK year-over-year).

• EBITDA: -4,733 KSEK (vs. -4,848 KSEK year-over-year).

• Net result: -5,929 KSEK (vs. -4,299 KSEK year-over-year).

• Gross margin improved to 83% from 76% year-over-year.

• Earnings per share: -0.23 SEK (vs. -0.28 SEK year-over-year).

Outlook and guidance

• Strategic investments in sales network and partner training are expected to drive sales growth and market presence in the latter part of 2024.

• Continued focus on expanding global distributor network, academic collaborations, and leveraging OTCQB listing to position as a leader in regenerative medicine technologies.